CEO Watcher

Consider buying Summit Therapeutics (SMMT), as two co-CEOs each purchased $6 million worth of stock following a recent 27% price decline. Similarly, four top executives at Envestnet (ENV) are buying shares for the first time in over two years, suggesting they see value after a 30% drop in the last year. Conversely, the CEO of LSI Industries (LYTS) made his first-ever discretionary sale after a price pop, indicating a potential near-term top. The co-CEOs at Ichor Holdings (ICHR) are also making their first-ever sales after a large run-up, signaling the stock may be overvalued. Finally, heavy insider selling at LoanDepot (LDI) and Carvana (CVNA) suggests management is cashing out on recent price surges, raising caution about their current valuations.

A director at Highcroft Mining made their first-ever stock purchases, investing a massive $60 million over the last few months, signaling extreme insider confidence. In contrast, a Senior Vice President at Designer Brands (DBI) sold their entire personal stake after the stock rallied over 40%. Historically, this specific executive's sales have been followed by an average stock decline of 27%. Another strong bearish signal comes from Aeye Inc. (LIDR), where a director is consistently selling shares after a massive 350% run-up. This director's previous sales have preceded average stock drops of over 50%, indicating a high risk of a major correction.

Multiple top executives at Enovis (ENOV), including the CEO, recently made their first-ever open-market stock purchases, signaling strong internal conviction that the stock is undervalued. Consider AudioEye (AEYE) for a longer-term hold, as a director's recent large purchase follows a historical pattern of the stock gaining over 50% within six months. Investors should be cautious with Tango Therapeutics (TNGX), as a major shareholder's recent $5.1 million sale has historically been followed by an average stock price decline of 42% within three months. The CEO of GigaCloud Technology (GCT) just made his first-ever unscheduled stock sale, a potential red flag from an insider with a strong track record of selling before price drops. Keep an eye on Cure Oncology, as the CEO's first-ever stock purchases precede a critical FDA decision due by November 30th, creating a high-risk, high-reward scenario.

A director at Broadcom (AVGO) purchased $1.23 million in stock, a notable move given their last purchase in 2023 preceded a 300% gain. Consider the opportunity in Permafix Environmental (PESI), where a director bought shares after a debunked rumor caused a significant price drop, signaling a potential recovery. Conversely, the CTO of CleanSpark (CLSK) and the CEO of GigaCloud (GCT) both made their first-ever unscheduled sales, a significant red flag from insiders with strong track records of timing price peaks. The CLSK insider's previous sales have historically preceded an average stock decline of over 20% within three months. Caution is also warranted for Coursera (COUR), as multiple executives continue to sell shares following its recent earnings pop.

The CEO of Curis Oncology (CRIS) has made his first-ever stock purchases ahead of a major FDA ruling expected by November 30th, signaling high confidence in a positive outcome. For energy exposure, consider MDU Resources (MDU), where the CFO recently made his largest-ever buys and has a perfect one-year track record on previous purchases. A key insider at Pango Therapeutics (PGTX) is making their largest-ever sales after a 250% stock run-up, suggesting a potential price decline. In the housing sector, consider avoiding D.R. Horton (DHI) due to significant insider selling. Instead, research competitors like Resideo Technologies (REZI) and Builders FirstSource (BLDR), which are seeing insider buying.